Acrivon Therapeutics Common Stock Probability of Future Stock Price Finishing Over 9.50
| ACRV Stock | 9.50 0.32 3.26% |
Acrivon |
Acrivon Therapeutics Target Price Odds to finish over 9.50
The tendency of Acrivon Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 9.50 | 90 days | 9.50 | under 4 |
Based on a normal probability distribution, the odds of Acrivon Therapeutics to move above the current price in 90 days from now is under 4 (This Acrivon Therapeutics Common probability density function shows the probability of Acrivon Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.32 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Acrivon Therapeutics will likely underperform. Moreover Acrivon Therapeutics Common has an alpha of 1.5812, implying that it can generate a 1.58 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta). Acrivon Therapeutics Price Density |
| Price |
Predictive Modules for Acrivon Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Acrivon Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Acrivon Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Acrivon Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Acrivon Therapeutics is not an exception. The market had few large corrections towards the Acrivon Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Acrivon Therapeutics Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Acrivon Therapeutics within the framework of very fundamental risk indicators.α | Alpha over NYSE Composite | 1.58 | |
β | Beta against NYSE Composite | 1.32 | |
σ | Overall volatility | 2.14 | |
Ir | Information ratio | 0.15 |
Acrivon Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Acrivon Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Acrivon Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Acrivon Therapeutics is way too risky over 90 days horizon | |
| Acrivon Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (60.39 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Acrivon Therapeutics generates negative cash flow from operations | |
| Acrivon Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 70.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from benzinga.com: Disposition of 558 shares by Miller Mary of Acrivon Therapeutics at 10.34 subject to Rule 16b-3 |
Acrivon Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Acrivon Stock often depends not only on the future outlook of the current and potential Acrivon Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Acrivon Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 22.1 M | |
| Cash And Short Term Investments | 127.5 M |
Acrivon Therapeutics Technical Analysis
Acrivon Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Acrivon Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Acrivon Therapeutics Common. In general, you should focus on analyzing Acrivon Stock price patterns and their correlations with different microeconomic environments and drivers.
Acrivon Therapeutics Predictive Forecast Models
Acrivon Therapeutics' time-series forecasting models is one of many Acrivon Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Acrivon Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Acrivon Therapeutics
Checking the ongoing alerts about Acrivon Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Acrivon Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Acrivon Therapeutics is way too risky over 90 days horizon | |
| Acrivon Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (60.39 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Acrivon Therapeutics generates negative cash flow from operations | |
| Acrivon Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 70.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from benzinga.com: Disposition of 558 shares by Miller Mary of Acrivon Therapeutics at 10.34 subject to Rule 16b-3 |
Check out Acrivon Therapeutics Backtesting, Acrivon Therapeutics Valuation, Acrivon Therapeutics Correlation, Acrivon Therapeutics Hype Analysis, Acrivon Therapeutics Volatility, Acrivon Therapeutics History as well as Acrivon Therapeutics Performance. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Acrivon Stock analysis
When running Acrivon Therapeutics' price analysis, check to measure Acrivon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics is operating at the current time. Most of Acrivon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics' price. Additionally, you may evaluate how the addition of Acrivon Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Acrivon Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acrivon Therapeutics. If investors know Acrivon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acrivon Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.74) | Return On Assets (0.26) | Return On Equity (0.41) |
The market value of Acrivon Therapeutics is measured differently than its book value, which is the value of Acrivon that is recorded on the company's balance sheet. Investors also form their own opinion of Acrivon Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Acrivon Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acrivon Therapeutics' market value can be influenced by many factors that don't directly affect Acrivon Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acrivon Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acrivon Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acrivon Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.